reviewClinical Cancer ResearchApr 15, 2005Closed access

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

National Cancer Institute · Dana-Farber Cancer Institute · +10 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

2-[(18)F]Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assesses a fundamental property of neoplasia, the Warburg effect. This molecular imaging technique offers a complementary approach to anatomic imaging that is more sensitive and specific in certain cancers. FDG-PET has been widely applied in oncology primarily as a staging and restaging tool that can guide patient care. However, because it accurately detects recurrent or residual disease, FDG-PET also has significant potential for assessing therapy response. In this regard, it can improve patient management by identifying responders early, before tumor size is reduced; nonresponders could discontinue futile therapy. Moreover, a reduction in…

Citation impact

669
total citations
FWCI
32.24
Percentile
100%
References
276
Citations per year

Authors

15

Topics & keywords

Keywords
  • Medicine
  • Positron emission tomography
  • Drug development
  • Clinical trial
  • Cancer
  • Prostate cancer
  • Oncology
  • Lung cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.